Patent ReferencesSubstituted morpholine derivatives and compositions Potentiation of drug response Treatment of attention-deficit/hyperactivity disorder Treatment of attention-deficit/hyperactivity disorder Patent #: 5696168 InventorAssigneeApplicationNo. 156289 filed on 09/17/1998US Classes:514/238.8, Chalcogen attached indirectly to the morpholine ring by acyclic nonionic bonding514/239.2, The chalcogen is bonded directly to two carbon atoms514/239.5, Carbocyclic ring attached indirectly to the morpholine ring by nonionic bonding514/438, The hetero ring is five-membered514/620, The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding514/649, Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain514/651, Ether oxygen is part of the chain514/653Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.)ExaminersPrimary: Krass, FrederickAttorney, Agent or FirmForeign Patent References
International ClassesA61K 031/535A61K 031/38 A61K 031/165 A61K 031/135 AbstractNorepinephrine reuptake inhibitors are used to treat oppositional defiant disorder.Other References
Field of SearchChalcogen attached indirectly to the morpholine ring by acyclic nonionic bondingThe chalcogen is bonded directly to two carbon atoms Carbocyclic ring attached indirectly to the morpholine ring by nonionic bonding The hetero ring is five-membered The nitrogen in R is an amino nitrogen attached indirectly to a ring by acyclic bonding Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain Ether oxygen is part of the chain Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.) | |